Clinical research increasingly supports the efficacy of GLP-1 RAs, such as liraglutide and semaglutide, in achieving significant weight reduction and improving OSA symptoms in certain patient populations. This evidence concerns the gene GLP1R and obstructive sleep apnea syndrome.